Company Shows Another Year of Record Growth and Advancements State College, PA (29 January 2019) – INDIGO Biosciences, Inc. (INDIGO), the recognized industry leader in nuclear receptor and in vitro toxicology testing solutions, has announced a record earnings year for 2019. With final numbers to be released to Company Shareholders in the upcoming weeks,Read More
INDIGO Expands Discovery Platform to Include Zebrafish Assays
Expansion Meets Industry Demand for Pre-Clinical Models for Cancer and Environmental Research State College, PA (23 January 2020) – INDIGO Biosciences, the recognized industry leader in nuclear receptor research, has announced the addition of four zebrafish assays to its portfolio. These additions both expand INDIGO’s robust portfolio of in vitro animal model assay systems andRead More
INDIGO Biosciences Welcomes New Member to Board of Directors
Mark McLoughlin Brings Four Decades of Healthcare Industry Experience to the Company’s Board State College, PA (13 August 2019) – INDIGO Biosciences, Inc. (INDIGO), the recognized industry leader in nuclear receptor and in vitro toxicology testing solutions, announced the appointment of Mark McLoughlin to the Company’s Board of Directors. Mark brings four decades of healthcare industry experience to theRead More
INDIGO Biosciences Announces Release of Assay Kit for Testing Multi-Drug Resistance
Testing Allows Researchers to Determine Possibility of Drug-Drug Interactions Before Clinical Trials State College, PA (19 June 2019) – INDIGO Biosciences, Inc. (INDIGO), the recognized industry leader in nuclear receptor and in vitro toxicology testing solutions, announced the addition of the Human MDR-1 / P-Glycoprotein Drug Interaction Assay to their portfolio. This kit expands INDIGO’sRead More
INDIGO Biosciences Announces Release of Predictive Liver Toxicity Assay Kit
By combining the advantages of upcyte hepatocytes with INDIGO’s industry-leading platform and science, the new hepatotoxicty assay kit helps researchers get the information they need to confidently advance their discovery processes.
INDIGO Biosciences Announces Release of Gene Expression Kit Utilizing upcyte® Hepatocytes
Portfolio Expansion Helps Researchers Move to the Next Stage of Discovery Faster State College, PA (December 5, 2018) – INDIGO Biosciences, Inc. (INDIGO), the recognized industry leader in nuclear receptor research, announced the addition of a gene expression assay kit featuring upcyte® hepatocytes to their portfolio. This addition both complements INDIGO’s industry-leading nuclear receptor assays andRead More
INDIGO Biosciences Receives Stephen M. Goodman Award from Keiretsu Forum
Most Valued Company Award Presented During Angel Capital Expo State College, PA (October 30, 2017) – INDIGO Biosciences, Inc. is pleased to announce that it was awarded the Stephen M. Goodman Most Valued Company Award at the Keiretsu Forum Angel Capital Expo. The Expo took place October 19, 2017 at the Union League in Philadelphia,Read More
INDIGO Announces Relaunch of Nuclear Receptor Resource Website
Premiere Educational Resource for Human Nuclear Receptor Information State College, PA (12/8/2016) INDIGO Biosciences, Inc. is pleased to announce the relaunch of the Nuclear Receptor Resource website. The NRR is a premier educational resource for information on the 48 human nuclear receptors. The NRR website has undergone a major redesign to make the site easierRead More
INDIGO Biosciences and Bertin Pharma Sign European Distribution Agreement
Ready-to-Use Nuclear Receptor Assay kits for over 20 disease states, including Cardiovascular and Metabolic Disease, Cancer, and Inflammation State College, PA (November 15, 2016) INDIGO Biosciences, the recognized industry-leader in Nuclear Receptor research, and Bertin Pharma have announced the completion of a European distribution agreement. Over 40 product references for studying nuclear receptors are nowRead More
INDIGO Offers Expansion of Industry-Leading FXR Assay
Meets industry demand for increased pre-clinical predictability. State College, PA (August 9, 2016) INDIGO Biosciences, the recognized industry leader in Nuclear Receptor research, announced the addition of the Mouse Farnesoid X Receptor (mFXR) assay to their FXR portfolio. This addition both complements INDIGO’s industry-leading human FXR assay and meets the demand for an expansion ofRead More